Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival.
Brück O, Dufva O, Hohtari H, Blom S, Turkki R, Ilander M, Kovanen P, Pallaud C, Ramos PM, Lähteenmäki H, Välimäki K, El Missiry M, Ribeiro A, Kallioniemi O, Porkka K, Pellinen T, Mustjoki S. Brück O, et al. Among authors: lahteenmaki h. Blood Adv. 2020 Jan 28;4(2):274-286. doi: 10.1182/bloodadvances.2019000792. Blood Adv. 2020. PMID: 31968078 Free PMC article.
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S. Ilander M, et al. Among authors: lahteenmaki h. Leukemia. 2017 May;31(5):1108-1116. doi: 10.1038/leu.2016.360. Epub 2016 Nov 28. Leukemia. 2017. PMID: 27890936 Free PMC article. Clinical Trial.
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.
Adnan Awad S, Brück O, Shanmuganathan N, Jarvinen T, Lähteenmäki H, Klievink J, Ibrahim H, Kytölä S, Koskenvesa P, Hughes TP, Branford S, Kankainen M, Mustjoki S. Adnan Awad S, et al. Among authors: lahteenmaki h. Blood Cancer J. 2022 Apr 20;12(4):69. doi: 10.1038/s41408-022-00667-9. Blood Cancer J. 2022. PMID: 35443743 Free PMC article. No abstract available.
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Huuhtanen J, Ilander M, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S. Huuhtanen J, et al. Among authors: lahteenmaki h. J Clin Invest. 2022 Sep 1;132(17):e152585. doi: 10.1172/JCI152585. J Clin Invest. 2022. PMID: 36047494 Free PMC article.
Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers.
Dufva O, Gandolfi S, Huuhtanen J, Dashevsky O, Duàn H, Saeed K, Klievink J, Nygren P, Bouhlal J, Lahtela J, Näätänen A, Ghimire BR, Hannunen T, Ellonen P, Lähteenmäki H, Rumm P, Theodoropoulos J, Laajala E, Härkönen J, Pölönen P, Heinäniemi M, Hollmén M, Yamano S, Shirasaki R, Barbie DA, Roth JA, Romee R, Sheffer M, Lähdesmäki H, Lee DA, De Matos Simoes R, Kankainen M, Mitsiades CS, Mustjoki S. Dufva O, et al. Among authors: lahteenmaki h. Immunity. 2023 Dec 12;56(12):2816-2835.e13. doi: 10.1016/j.immuni.2023.11.008. Immunity. 2023. PMID: 38091953 Free article.
Active MMP-8 point-of-care (PoC)/chairside enzyme-test as an adjunctive tool for early and real-time diagnosis of peri-implantitis.
Lähteenmäki H, Tervahartiala T, Räisänen IT, Pärnänen P, Mauramo M, Gupta S, Sampson V, Rathnayake N, Heikkinen AM, Alassiri S, Gieselmann DR, Frankenberger R, Sorsa T. Lähteenmäki H, et al. Clin Exp Dent Res. 2022 Apr;8(2):485-496. doi: 10.1002/cre2.537. Epub 2022 Feb 3. Clin Exp Dent Res. 2022. PMID: 35118828 Free PMC article.
Proviral integration site for Moloney murine leukemia virus (PIM) kinases promote human T helper 1 cell differentiation.
Tahvanainen J, Kyläniemi MK, Kanduri K, Gupta B, Lähteenmäki H, Kallonen T, Rajavuori A, Rasool O, Koskinen PJ, Rao KV, Lähdesmäki H, Lahesmaa R. Tahvanainen J, et al. Among authors: lahteenmaki h. J Biol Chem. 2013 Feb 1;288(5):3048-58. doi: 10.1074/jbc.M112.361709. Epub 2012 Dec 3. J Biol Chem. 2013. PMID: 23209281 Free PMC article.
23 results